Business Wire

Statement by Aviator LLC

6.8.2025 16:18:00 CEST | Business Wire | Press Release

Share

Aviator LLC today issued a statement clarifying the nature and scope of a recent UK court ruling following public statements made by SPRIBE OU regarding interim injunction proceedings.

According to Nikoloz Gogilidze, legal representative for Aviator LLC, the recent court order was an interim injunction with limited scope and commercial impact.

Gogilidze highlights the key points of the proceedings, which appear to have been mischaracterized in some media reports.

Nature of the Court Order: The ruling represents an interim injunction granted at a preliminary procedural stage, not a final determination on the merits of the underlying dispute. Such orders are designed to maintain the status quo pending full trial proceedings.

Commercial Impact: The injunction has no practical effect as neither Aviator LLC nor its IP rights licensee had any existing plans to enter the UK market at this time. The company has not applied for the required UK Gambling Commission gaming license, a process that typically takes approximately one year to complete.

Scope of Restrictions: The court rejected several requests made by SPRIBE OU, including attempts to prevent Aviator LLC from making public statements about its intellectual property rights. Five of the eight relief requests initially sought by SPRIBE OU were withdrawn during the proceedings. Those five reliefs were: Distributing any emails or press releases in the UK (which Aviator LLC wasn’t doing in any event); Making any statements - public or private – asserting Aviator LLC’s ownership of the Aviator IP; Stating that SPRIBE OU isn’t the rightful owner of said IP; Posting any of above-mentioned statements on the www.aviator.studio website.

The UK dispute was initiated by Aviator LLC in late 2024, following successful proceedings in Georgia (Case No. 2/1413-24). In the Georgian case, courts including the Supreme Court of Georgia ruled in favor of Aviator LLC on copyright infringement and bad faith trademark registration claims.

The UK proceedings are based on similar legal grounds, specifically allegations of bad faith trademark registration and copyright infringement relating to SPRIBE OU's UK trademarks.

As is standard practice, SPRIBE OU was required to provide an undertaking to compensate Aviator LLC for any damages if the interim injunction is later determined to have been wrongly granted. The preliminary injunction does not prevent Aviator LLC from applying for a UK gambling license.

“The key point to understand at this juncture is that the UK proceedings are likely to conclude before any licence application is processed, rendering the interim injunction commercially irrelevant,” says Gogilidze. “Importantly, however, the preliminary injunction expressly does not prevent Aviator LLC or its licensee from applying for a gambling licence in the United Kingdom – unfortunately this appears to have been mischaracterized in some media reports.”

The parties are engaged in parallel proceedings in multiple jurisdictions, with the UK case representing one aspect of the broader intellectual property dispute.

Aviator LLC expects to continue pursuing its claims through the appropriate legal channels across relevant jurisdictions. The company remains focused on protecting what it considers to be its legitimate intellectual property rights, and rejects efforts by other parties aimed at misleading the industry with regard to the substance of status quo court orders.

“We look forward to presenting the merits of our claim in the UK as well as other markets, and we remain confident of our ultimate success in this matter,” Gogilidze said.

For further information, please contact info.aviator@mikadze.ge.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250806355689/en/

Contacts

Nikoloz Gogilidze, info.aviator@mikadze.ge

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye